NFKB1 and neoplasm: Aberrant NF-κB pathway activation directly induces PD-L1 transcription and regulatory T cell proliferation, indicating NF-κB as a promising therapeutic target for modulating the immunosuppressive tumor microenvironment in CRC [26].